Form 4: Aehr Test Systems Director Sells Shares

Sentiment:

Insider Transaction Report 13 February 2026 4:48 PM

Aehr Test Systems Director Rhea J. Posedel reported the sale of 13,998 shares of common stock at $30.0151 per share, effective February 13, 2026, under a pre-arranged 10b5-1 plan.

Worse than expectedA director's sale of a significant number of shares (13,998) can be interpreted by the market as a lack of confidence or a belief that the stock price may not appreciate significantly in the near term.While executed under a 10b5-1 plan, which mitigates the immediate 'timing' signal, the decision to establish such a plan for a sale still reflects an insider's long-term view.

Summary

Rhea J. Posedel, a Director of Aehr Test Systems (AEHR), reported a sale of common stock.
The transaction involved the disposition of 13,998 shares of common stock.
The shares were sold at a price of $30.0151 per share.
The transaction date is February 13, 2026.
The sale was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged transaction.
Following the transaction, Ms. Posedel will beneficially own 456,979 shares directly and 71,163 shares indirectly through a trust.
The reported beneficial ownership includes shares subject to unvested restricted stock units.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal due to a director's sale of shares, although the pre-arranged 10b5-1 plan somewhat lessens the immediate negative impact compared to an unplanned sale.

Negatives

A director selling 13,998 shares of common stock, even under a 10b5-1 plan, can be perceived as a negative signal regarding future stock performance.

Industry Context

StockSavvy.ai notes that insider sales, even those pre-scheduled under Rule 10b5-1 plans, are routinely monitored by investors for potential insights into management's perception of future company prospects, particularly within the semiconductor test and burn-in equipment industry where market sentiment can be highly reactive to such signals.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Power of Attorney Grant	Rhea J. Posedel granted a Power of Attorney to Gayn Erickson, Chris Siu, Adil Engineer, and Vernon Rogers to execute Section 16 filings on her behalf.	2023-06-02	Streamlines compliance for insider reporting requirements for the named director.

Related Party Transactions

Rhea J. Posedel, a Director, sold 13,998 shares of Aehr Test Systems common stock at $30.0151 per share.

Stakeholder Impact

Shareholders: May interpret the director's sale as a negative signal, potentially leading to downward pressure on the stock price.

Key Dates

Date	Description
2023-06-02	Date Power of Attorney was executed by Rhea J. Posedel.
2026-02-13	Date of the reported transaction (sale of common stock).

Recommendation

hold

The sale by a director, even under a pre-arranged 10b5-1 plan, introduces a degree of caution. While not a definitive 'sell' signal given the remaining substantial holdings and the planned nature of the transaction, it suggests that the insider sees less immediate upside. Investors should 'hold' and monitor future insider activity and company performance.

Keywords

Aehr Test Systems, AEHR, Form 4, Insider Trading, Stock Sale, Director, Rhea J. Posedel, 10b5-1 Plan, Common Stock

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.